603079.SH
圣达生物
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 12.63
−9.98%Year over year
Reported trailing growth
- Revenue
- -1.8%
- EBITDA
- —
- EBIT
- +6.7%
- EPS
- +6.4%
- Free cash flow
- +149.7%
- Operating cash flow
- +16.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.6%
- EBITDA
- +14.2%
- EBIT
- +30.4%
- Net income
- +25.4%
- EPS
- +24.8%
- Free cash flow
- +69.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026